Dan Mandell
@dj_mandell
Followers
261
Following
150
Statuses
120
CEO and Co-founder of @GRO_bio. Synthetic biology, protein engineering, and the future of biotechnology.
Cambridge, MA
Joined October 2021
RT @gro_bio: Our CEO Dan Mandell had a great discussion with the legendary Dr. George Church on the future of technology and synthetic biol…
0
1
0
RT @gro_bio: Congratulations to Bharat Adkar on his 3-year anniversary with GRObio! Bharat has applied his expertise in #computationalprot…
0
1
0
RT @gro_bio: Today we celebrate Principal Scientist, Cory Dunn, for his contributions over the past 3 years at GRObio! Cory has spearheade…
0
1
0
RT @gro_bio: Scott Frankenthaler, Manager, Corporate Development is attending the 10th annual G-CAN International Research Symposium! Orga…
0
1
0
RT @gro_bio: Congratulations to Silvere Pagant on his 3-year anniversary with GRObio! Silvere has driven major advances in our ProGly-Uric…
0
1
0
RT @gro_bio: Join us in celebrating Nadine Anderson on her 3-year anniversary with GRObio! Nadine’s recent promotion to Senior Scientist I…
0
1
0
RT @BiotechTVHQ: 𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: George Church on the key innovations in synthetic biology that are poised to make contributi…
0
1
0
RT @BiotechTVHQ: 𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: George Church on computer augmentation of the brain and making progress on diseases of aging…
0
1
0
Had a blast sitting down with my @gro_bio co-founder and Scientific Advisory Board Chair @geochurch to discuss genomically recoded organisms, principles of founder-led bio, the near-term impact of synthetic biology on biotechnology, planetary colonization, brain mapping, and more. Many thanks to @bradloncar and @BiotechTVHQ for having us!
1
0
8
RT @bradloncar: Honored to have George Church in the podcast studio today. This episode will air on Tuesday. 30+ minutes of his take on the…
0
6
0
RT @gro_bio: Congratulations to Maidul Islam on his two-year anniversary with GRObio! Maidul has been an invaluable part of our team, leve…
0
1
0
So proud of this team – we had a terrifically fun day keeping it (sur)real!
In July, GRObio successfully closed a $60M Series B financing. To celebrate this milestone, our team embarked on a "Museum Hack" scavenger hunt at the @mfaboston, followed by an unforgettable dinner brimming with creativity, inspiration, and plenty of laughter. This achievement wouldn’t have been possible without the dedication and unwavering support of our incredible team. Thank you all for your commitment — here’s to the future of groundbreaking innovation and more exciting adventures ahead! On we GRO! #SeriesB #TeamCelebration #mfaBoston
0
0
8
RT @gro_bio: Join us in celebrating Meghan Reedy, Senior Research Associate, on her 2-year anniversary with GRObio! Meghan has developed k…
0
1
0
RT @gro_bio: Congratulations to Anushka Saha on her one-year anniversary with GRObio! Anushka is a dedicated team player who has developed…
0
1
0
RT @gro_bio: Congratulations to Derek Clay on his 2-year anniversary with GRObio! As a key member of our Biofoundry team, Derek has contri…
0
1
0
RT @gro_bio: August marks GRObio's 7th anniversary! Since 2017, we have made great strides on our mission to leverage the unprecedented ca…
0
1
0
RT @gro_bio: Christopher J Gregg, PhD, Chief Science Officer, and Cory Dunn, Principal Scientist, will be speaking at the 2024 Genetic Code…
0
1
0
RT @gro_bio: Join us in celebrating Mark Cerutti, Senior Automation Engineer, on his 3-year anniversary at GRObio! Mark supports GRObio's…
0
1
0
RT @frankvinluan: A key limitation of protein drugs: The body sees them as foreign, triggering an immune response to the protein. @gro_bio…
0
2
0
I am thrilled to announce @gro_bio's $60.3M Series B financing, co-led by @atlasventure and Access Biotechnology! This financing is the culmination of an enormous body of work by our entire company, including our GRO platform, product pipeline, and business development personnel, and I could not be more proud of our team. GRObio has presented impressive pre-clinical data across multiple disease indications, and this financing will power the acquisition of efficacy data in clinical trials for our lead program in chronic refractory gout. It will further advance and broaden our pipeline, as well as enable next-gen approaches to drugs like ADCs through the simultaneous attachment of distinct payloads through multiple non-standard amino acids. I'm excited to partner with @KevinBitterman, Dan Becker, @jernejgodec and Christine Borowski, who are reuniting via GRObio after previous successful co-investments, including Mariana Oncology and their recent acquisition by Novartis. With this financing, together with the continued participation of our Series A investors including @LeapsByBayer, Redmile Group, @digitalisvc, and @iendeavors, we have assembled the ideal syndicate to advance GRObio to a clinical-stage company. Our team is eager to begin this new chapter, and to rise to meet its attendant challenges. And most importantly, we are grateful for the opportunity to bring our therapies to the patients who need them. Many thanks to @hannah_reports at @BosBizJournal, @bradloncar at @BiotechTVHQ, and @RLCscienceboss at @endpts, for excellent early coverage of our financing. Press release: Boston Business Journal: Biotech TV: Biotech TV: Endpoints: On we GRO!
9
4
71